會(huì)員.png)
5
當(dāng)前位置：北京博奧森生物技術(shù)有限公司>>公司動(dòng)態(tài)>>【2024年2月文獻(xiàn)戰(zhàn)報(bào)】Bioss抗體新增高分文獻(xiàn)精彩呈現(xiàn)
【2024年2月文獻(xiàn)戰(zhàn)報(bào)】Bioss抗體新增高分文獻(xiàn)精彩呈現(xiàn)
截止目前，引用Bioss產(chǎn)品發(fā)表的文獻(xiàn)共29281篇，總影響因子141751.15分，發(fā)表在Nature, Science, Cell以及Immunity等頂級(jí)期刊的文獻(xiàn)共68篇，合作單位覆蓋了清華、北大、復(fù)旦、華盛頓大學(xué)、麻省理工學(xué)院、東京大學(xué)以及紐約大學(xué)等國(guó)際研究機(jī)構(gòu)上百所。
我們每月收集引用Bioss產(chǎn)品發(fā)表的文獻(xiàn)。若您在當(dāng)月已發(fā)表SCI文章，但未被我公司收集，請(qǐng)致電Bioss，我們將贈(zèng)予現(xiàn)金鼓勵(lì)，金額標(biāo)準(zhǔn)請(qǐng)參考“發(fā)文章 領(lǐng)獎(jiǎng)金"活動(dòng)頁(yè)面。
近期收錄2024年2月引用Bioss產(chǎn)品發(fā)表的文獻(xiàn)共363篇（圖一，綠色柱），文章影響因子(IF) 總和高達(dá)2298.3，其中，10分以上文獻(xiàn)45篇（圖二）。
圖一
圖二
本文主要分享引用Bioss產(chǎn)品發(fā)表文章至Nature, Immunity, Cancer Cell等期刊的5篇 IF＞15 的文獻(xiàn)摘要，讓我們一起欣賞吧。
Molecular Cancer [IF=37.3]
文獻(xiàn)引用產(chǎn)品：bsm-33070M
Ki-67 Mouse mA | IHC
作者單位：重慶醫(yī)科大學(xué)
摘要：CircPDHK1 was upregulated in ccRCC tissues and closely related to WHO/ISUP stage, T stage, distant metastasis, VHL mutation and Ki-67 levels. CircPDHK1 had a functional internal ribosome entry site (IRES) and encoded a novel peptide PDHK1-241aa. Functionally, we confirmed that PDHK1-241aa and not the circPDHK1 promoted the proliferation, migration and invasion of ccRCC. Mechanistically, circPDHK1 was activated by HIF-2A at the transcriptional level. PDHK1-241aa was upregulated and interacted with PPP1CA, causing the relocation of PPP1CA to the nucleus. This thereby inhibited AKT dephosphorylation and activated the AKT-mTOR signaling pathway.
Cellular & Molecular Immunology [IF=24.1]
文獻(xiàn)引用抗體：
bs-2789R; Tap1 Rabbit pAb | FC
bs-2374R; TAP2 Rabbit pAb | FC
作者單位：北京大學(xué)
摘要：CD4+ T cells can "help" or "license" conventional type 1 dendritic cells (cDC1s) to induce CD8+ cytotoxic T lymphocyte (CTL) anticancer responses, as proven in mouse models. We recently identified cDC1s with a transcriptomic imprint of CD4+ T-cell help, specifically in T-cell-infiltrated human cancers, and these cells were associated with a good prognosis and response to PD-1-targeting immunotherapy. Here, we delineate the mechanism of cDC1 licensing by CD4+ T cells in humans. Activated CD4+ T cells produce IFNβ via the STING pathway, which promotes MHC-I antigen (cross-)presentation by cDC1s and thereby improves their ability to induce CTL anticancer responses. In cooperation with CD40 ligand (L), IFNβ also optimizes the costimulatory and other functions of cDC1s required for CTL response induction. IFN-I-producing CD4+ T cells are present in diverse T-cell-infiltrated cancers and likely deliver “help" signals to CTLs locally, according to their transcriptomic profile and colocalization with “helped/licensed" cDCs and tumor-reactive CD8+ T cells. In agreement with this scenario, the presence of IFN-I-producing CD4+ T cells in the TME is associated with overall survival and the response to PD-1 checkpoint blockade in cancer patients.
ADVANCED FUNCTIONAL MATERIALS [IF=19.0]
文獻(xiàn)引用產(chǎn)品：bs-4917R
Osteocalcin Rabbit pAb | IF
作者單位：北京大學(xué)口腔醫(yī)院
ACS Nano [IF=17.1]
文獻(xiàn)引用抗體：
bs-0292P; BSA-V
D-9106; DAPI
bsm-33070M; Ki-67 Mouse mAb | IF
作者單位：北京大學(xué)
Advanced Science [IF=15.1]
文獻(xiàn)引用抗體：
bs-0292P-FITC; BSA / FITC | IF
bsm-60235R; Keratin 6 Recombinant Rabbit mAb | IF
作者單位：南方醫(yī)科大學(xué)
摘要：To address current challenges in effectively treating large skin defects caused by trauma in clinical medicine, the fabrication, and evaluation of a novel radially aligned nanofiber scaffold (RAS) with dual growth factor gradients is presented. These aligned nanofibers and the scaffold's spatial design provide many all-around “highways" for cell migration from the edge of the wound to the center area. Besides, the chemotaxis induced by two growth factor gradients further promotes cell migration. Incorporating epidermal growth factor (EGF) aids in the proliferation and differentiation of basal layer cells in the epidermis, augmenting the scaffold's ability to promote epidermal regeneration. Concurrently, the scaffold-bound vascular endothelial growth factor (VEGF) recruits vascular endothelial cells at the wound's center, resulting in angiogenesis and improving blood supply and nutrient delivery, which is critical for granulation tissue regeneration. The RAS+EGF+VEGF group demonstrates superior performance in wound immune regulation, wound closure, hair follicle regeneration, and ECM deposition and remodeling compared to other groups. This study highlights the promising potential of hierarchically assembled nanofiber scaffolds with dual growth factor gradients for wound repair and tissue regeneration applications.